Last reviewed · How we verify
Single-entity oral triptans
At a glance
| Generic name | Single-entity oral triptans |
|---|---|
| Also known as | Zomig® is a registered trademark of AstraZeneca, Maxalt® is a registered trademark of Merck & Co, Inc, Relpax® is a registered trademark of Pfizer, Frova® is a registered trademark of Elan Pharmaceuticals/UCB Pharma |
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Safety and Psychological Effects of Psilocybin and D-Serine Formulation in Healthy Volunteers (PHASE1)
- A Combination Product of Sumatriptan and Naproxen Sodium Versus Single-entity Oral Triptans: An Analysis of Real World Data
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Single-entity oral triptans CI brief — competitive landscape report
- Single-entity oral triptans updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI